论文部分内容阅读
与常规治疗组相比 ,1型糖尿病患者接受强化治疗 (以达到血糖和糖化血红蛋白浓度接近正常水平为目的 )后微血管并发症的发生风险显著较低 ,为评价这种有益作用是否能持续 ,作者在糖尿病控制和并发症试验研究 (ＤＣＣＴ)结束后的 4年期间 ,比较了以往使用的强化治疗和常规治疗方
The risk of microvascular complications is significantly lower in patients with type 1 diabetes compared with those in the usual care group (with the goal of achieving near normal levels of blood glucose and HbA1c) and to assess whether this beneficial effect is sustained During the four years after the end of the Diabetes Control and Complications Trial Study (DCCT), previously used intensive and routine treatments